Name: 글로벌 시장 동향
SKU: BT2315
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 난발현 단백질 시장은 2022년 40억 760만 달러 규모에 달했으며, 2030년에는 90억 5,210만 달러까지 성장할 것으로 예상됩니다. 난발현 단백질 시장은 예측 기간(2023~2030년) 동안 연평균 11.0%의 성장률을 보일 것으로 전망됩니다. 주요 전략적 인수합병이 난발현 단백질 시장 성장을 견인하고 있습니다.
예를 들어, 생명과학 항체 및 시약 분야의 세계적인 공급업체인 바이오레전드(BioLegend)를 건강한 사회를 위한 혁신에 전념하는 기업인 퍼킨엘머(PerkinElmer, Inc.)가 인수하는 거래가 완료되었습니다. 인수 금액은 약 52억 5천만 달러였습니다. 퍼킨엘머 역사상 최대 규모의 이번 인수를 통해 회사는 세포 계측, 단백질 유전체학, 다중 분석, 재조합 단백질, 자기 세포 분리 및 생물 공정 등 고성장 산업 분야에서 생명과학 사업을 더욱 확장할 수 있게 될 것입니다.

고처리량 기술의 활용과 더불어 수많은 유기체의 게놈에 존재하는 DNA 코딩 서열을 정확하게 찾아내는 기술은 재조합 단백질 생산 분야를 크게 발전시켰습니다. 지난 몇 년간 생물학적 제제에 대한 수요가 증가했으며, 이러한 추세는 앞으로도 지속될 것으로 보입니다. 특히 선호되는 발현 시스템 중 하나는 대장균(Escherichia coli) 세포를 기반으로 하는 시스템인데, 이는 비용 효율성이 높을 뿐만 아니라 다양한 보조제를 사용할 수 있다는 장점이 있습니다.
하지만 이 시스템에서는 원하는 유전자의 상당 부분이 효율적으로 발현되지 않거나, 발현된 단백질이 덩어리를 형성하거나 예상되는 생물학적 활성을 나타내지 못해 결국 폐기되는 경우가 발생합니다. 따라서 이러한 단백질에는 특수한 발현 시스템이 필요하며, 이는 난발현 단백질 시장의 성장을 촉진하고 있습니다.

시장 동향
단백질 생물학적 제제에 대한 수요 증가가 난발현 단백질 시장 성장을 견인하고 있습니다.
암, 자가면역 질환 및 기타 심각한 질병과 같은 대부분의 만성 질환은 생물학적 제제를 사용하여 치료됩니다. 이러한 생물학적 제제에는 백신, 혈액 및 혈액 성분, 재조합 치료 단백질 등이 포함됩니다. 따라서 앞서 언급한 만성 질환을 비롯한 여러 질환의 증가 추세는 생물학적 제제에 대한 수요를 촉진하고 있으며, 이는 전 세계적으로 발현이 어려운 단백질 시장의 성장을 견인하고 있습니다.
예를 들어, 토실리주맙(tocilizumab)과 소트로비맙(sotrovimab)과 같은 여러 단클론항체(mAb)와 밤라니비맙(bamlanivimab)과 에테세비맙(etesevimab)의 병용 투여는 코로나19(경증~중등증) 치료를 위한 긴급사용승인(EUA)을 받았으며, 에부셸드(evusheld, 틱사게비맙과 실가비맙의 병용 패키지)는 감염 예방을 위한 예방약으로 승인되었습니다. 이러한 약물 중 다수는 2022년까지 미국 식품의약국(FDA)의 승인을 받을 예정이었습니다.
시장의 기술 발전은 시장 참여자들에게 성장 기회를 제공합니다.
항체, 성장 인자, 나노항체, 고품질 단백질 식품 성분과 같은 단백질의 이종 생산에 대한 관심이 증가함에 따라, 미세유체 기술은 단백질 발현 연구에 사용되는 가장 중요하고 최첨단 기술 중 하나입니다. 효과적인 생산 숙주에 대한 필요성이 증가하고 있습니다. 연구 결과는 DBM 스크리닝이 이종 단백질 생산 및 분비를 위한 세포 공장 개선에 강력한 도구로서 효과적임을 입증했습니다.
또한, 마이크로유체 항체 포획(MAC) 칩이라는 최첨단 기술을 활용하여 단일 세포 수준에서 단백질 발현 및 인산화 정도를 평가했습니다. 마이크로유체 기술의 발전은 종양 세포와 비종양 세포의 분석 및 평가를 위한 신뢰할 수 있는 솔루션을 제공하며, 향후 몇 년 동안 시장에 유망한 성장 기회를 제시하고 있습니다.

COVID-19 영향 분석
COVID-19 분석에는 COVID-19 이전 시나리오, COVID-19 기간 시나리오, COVID-19 이후 시나리오와 함께 가격 변동(팬데믹 기간 및 이후의 가격 변화를 COVID-19 이전 시나리오와 비교), 수요-공급 양상(무역 제한, 봉쇄 및 그로 인한 문제로 인한 수요와 공급의 변화), 정부 정책(정부 기관의 시장, 부문 또는 산업 활성화 정책), 제조업체의 전략적 조치(제조업체가 COVID-19 관련 문제를 완화하기 위해 취한 조치)가 포함됩니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 분쟁은 해당 지역의 주요 시장 참여자가 부재하기 때문에 전 세계 난발현 단백질 시장에 미치는 영향이 미미할 것으로 예상됩니다. 그러나 원자재, 제품 및 장비의 수출입은 예측 기간 동안 전 세계 난발현 단백질 시장에 약간의 영향을 미칠 것으로 예상됩니다.

글로벌 경기 침체 영향 분석
의료 산업 역시 경기 침체의 영향을 완전히 피할 수는 없습니다. 과거 경기 침체기에는 의료기관들이 인력 감축이나 고용 동결을 경험하기도 했습니다. 하지만 필수적인 산업 특성상 다른 산업에 비해 상대적으로 잘 대처하는 편입니다. 경기 침체는 연구 투자 감소로 이어져 지난 몇 년간 시장 성장에 부정적인 영향을 미쳤습니다.
인공지능(AI) 영향 분석
2023년 2월 워싱턴 대학교 의과대학(UW Medicine)에서 발표한 논문에 따르면, 과학자들이 머신러닝을 활용하여 화학 반응을 촉진하는 단백질인 새로운 효소를 개발했습니다. 연구팀은 딥러닝 기반의 인공지능 알고리즘을 개발하여 루시페라제라는 발광 효소를 만들어냈습니다. 실험실 테스트 결과, 이 새로운 효소는 특정 화학 물질을 식별하고 매우 효율적으로 빛을 방출하는 것으로 나타났습니다. AI를 활용한 이러한 단백질 연구의 발전은 향후 몇 년 동안 전 세계 난용성 단백질 시장에 긍정적인 영향을 미칠 것으로 예상됩니다.

시장 세분화 분석
전 세계 난발현 단백질 시장은 단백질 종류, 기술, 응용 분야 및 지역별로 세분화됩니다.
세포 외 단백질 합성(CFPS) 부문은 예측 기간 동안 난발현 단백질 시장 점유율의 대부분을 차지할 것으로 예상됩니다.
세포 외 단백질 합성 부문은 2022년 14억 6,080만 달러 규모로 전체 난발현 단백질 시장의 약 36.4%를 차지했으며, 예측 기간 동안 지속적인 성장이 예상됩니다. 세포 외 단백질 합성 기술의 장점과 활발한 연구 활동이 예측 기간 동안 해당 부문의 성장을 촉진할 것으로 전망됩니다.
예를 들어, 2022년 11월 한국에서는 세포 외 단백질 합성(CFPS) 시스템을 이용한 박테리오파지 및 대사 경로 재구성을 위한 다양한 유전자 발현 연구가 진행되었습니다. 개방형 설계 덕분에 CFPS는 새로운 바이러스(또는 바이러스 유사 입자(VLP)) 또는 합성 경로를 자유롭게 설계하는 데 이상적입니다. CFPS는 각 절차별 세포 배양 단계를 생략함으로써 합성 생물학의 설계-구축-테스트 프로세스를 가속화할 수 있습니다. 또한, 바이오 파운드리 형태로 구현될 경우 자동화에 더욱 유리하여 연구 속도를 더욱 높일 수 있습니다.
지리적 분석
유럽은 예측 기간 동안 전 세계 난발현 단백질 시장에서 두 번째로 큰 점유율을 차지할 것으로 예상됩니다.
유럽은 정부 및 비정부 기관의 투자 증가에 힘입어 약 25.2%의 상당한 시장 점유율을 확보할 것으로 전망됩니다. 예를 들어, 새로운 종류의 치료용 RNA를 연구하는 영국의 바이오테크 스타트업인 트랜신 테라퓨틱스(Transine Therapeutics)는 2022년 5월 시드 펀딩으로 460만 파운드(580만 달러)를 추가로 유치했습니다. 이 투자는 신규 투자자인 에피다렉스 캐피털(Epidarex Capital)이 주도했으며, 기존 투자사인 치매 발견 펀드(Dementia Discovery Fund, DDF)도 참여했습니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Reaction Biology(Cobepa), LifeSensors Inc., Lucigen(LGC Group), BioLegend, Inc.(PerkinElmer Inc.), OriGene Technologies, Inc., R&D Systems, Enzo Life Sciences, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., Merck KGaA 등이 있습니다.
보고서 구매 이유

• 제품, 응용 분야 및 지역별 글로벌 난발현 단백질 시장 세분화를 시각화하고 주요 상업적 자산과 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 난발현 단백질 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품 목록이 포함된 Excel 파일 형태의 제품 맵핑을 제공합니다.

글로벌 난발현 단백질 시장 보고서는 약 53개의 표, 54개의 그림, 그리고 195페이지 분량으로 구성될 예정입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The global difficult-to-express proteins market reached US$ 4,007.6 million in 2022 and is projected to reach up to US$ 9,052.1 million by 2030. The difficult-to-express proteins market is expected to exhibit a CAGR of 11.0% during the forecast period (2023-2030). Key strategy acquisitions drive the difficult-to-express proteins market growth.
For instance, the acquisition of BioLegend, a top global supplier of life science antibodies and reagents, by PerkinElmer, Inc., a company dedicated to innovation for a healthier society, has been finalized. The acquisition cost was about US$ 5.25 billion. The largest acquisition in PerkinElmer's history will allow the company to further develop its life science business in high-growth industries like cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing.
The pinpointing of DNA coding series retained in the genome of numerous organisms associated with employing high throughput techniques has fueled the domain of recombinant protein production. In the past few years, the demand for biological compounds has grown and appears to hold a long run on the market. One of the considerably favored expression systems is established on Escherichia coli cells, which apart from being cost-effective, counts on an extensive preference for aids.
Nevertheless, a substantial portion of the genes of interest are not efficiently expressed in this design, or the expressed proteins accumulated within forms lumps or lack the expected biological action, being eventually dumped. Thus, such proteins require a specialized expression system, which is boosting the difficult-to-express proteins market growth.
Market Dynamics
The increasing demand for protein biologics is driving the difficult-to-express proteins market growth.
Most chronic diseases such as cancer, autoimmune diseases, and other serious diseases are treated using biologics. These biologics include vaccines, blood and blood components, and recombinant therapeutic proteins. Therefore, the rising cases of the mentioned chronic diseases among others are fueling the demand for biologics, thereby boosting the global difficult-to-express proteins market growth.
For instance, several mAbs, such as tocilizumab and sotrovimab, and the co-administration of bamlanivimab and etesevimab, had received EUA for COVID-19 treatment (mild to moderated) and evusheld (co-package of tixagevimab with cilgavimab) was authorized as a prophylactic for the prevention of the infection. Several of these drugs were to receive drug approvals from the FDA by 2022.
The technological advancements in the market provide the market players with growth opportunities
With growing interest in the heterologous production of proteins like antibodies, growth factors, nanobodies, and high-quality protein food ingredients, microfluidics is one of the most significant and cutting-edge techniques used in studies and research on protein expression. There is a rising need for effective production hosts. The outcomes demonstrated the effectiveness of DBM screening as a powerful tool for improving cell factories for the production and secretion of heterologous proteins.
Moreover, a cutting-edge technology called the Microfluidic Antibody Capture (MAC) chip is employed to assess the degree of protein expression and phosphorylation at the single-cell level. Microfluidics technology advancements have offered reliable solutions for the analysis and assessment of tumorous and non-tumorous cells, presenting the market with lucrative growth opportunities in the upcoming years.
COVID-19 Impact Analysis
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a minimal impact on the global difficult-to-express proteins market, owing to the absence of key market players in this region. However, the impact of the import and export of raw materials, products, and devices is anticipated to have little influence over the global difficult-to-express proteins market over the forecast period.
Global Recession Impact Analysis
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. The recession has led to a decrease in research investments, which has negatively impacted the market growth in the past few years.
Artificial Intelligence Impact Analysis
According to an article sourced from the University of Washington School of Medicine/UW Medicine published in February 2023, scientists have utilized machine learning to construct brand-new enzymes, which are proteins that boost chemical reactions. The research team developed deep-learning, artificial intelligence algorithms that constructed light-emitting enzymes called luciferases. Laboratory testing proved that the new enzymes can identify distinct chemicals and radiate light with remarkable efficiency. Such developments in protein research with AI are expected to positively impact the global difficult-to-express protein market in the upcoming years.
Segment Analysis
The global difficult-to-express proteins market is segmented based on proteins, technology, applications, and region.
The cell-free protein synthesis segment is estimated to hold a majority of the difficult-to-express proteins market share during the forecast period.
The cell-free protein synthesis segment was valued at US$ 1,460.8 million in 2022, holding about 36.4% of the total difficult-to-express protein market share and is estimated to grow throughout the forecast period. The advantages of cell-free protein synthesis technology and increasing research activities are expected to boost segment growth during the forecast period.
For instance, in November 2022, multiple gene expressions in cell-free protein synthesis (CFPS) systems for reconstructing bacteriophages and metabolic pathways were done in Korea. Because of its open design, CFPS is ideal for designing novel viruses (or virus-like particles (VLPs)) or synthetic pathways with great liberty. CFPS can rush up the design-build-test process of synthetic biology by bypassing cell culture per procedure. CFPS would be additionally automation-friendly in bio-foundry form for the exact cause, which could additionally quicken up research.
Geographical Analysis
Europe is estimated to hold the second-largest share of the global difficult-to-express proteins market during the forecast period.
Europe is estimated to have a considerable market share of about 25.2% owing to the increased investment from government and non-government organizations. For example, Transine Therapeutics, a UK biotech startup researching a novel class of therapeutic RNAs, raised £4.6M (USD 5.8 million) in additional seed funding in May 2022. The financing was led by new investor Epidarex Capital, with a current investment, the Dementia Discovery Fund, also participating (DDF).
Competitive Landscape
The major global players in the market include Reaction Biology (Cobepa), LifeSensors Inc., Lucigen(LGC Group), BioLegend, Inc.(PerkinElmer Inc.), OriGene Technologies, Inc., R&D Systems, Enzo Life Sciences, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., and Merck KGaA, among others.
Why Purchase the Report?
• To visualize the global difficult-to-express proteins market segmentation based on product, application, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of difficult-to-express proteins market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global difficult-to-express proteins market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Proteins
3.2. Snippet by Technology
3.3. Snippet by Application
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Advancements in Cell-free Protein Synthesis Platforms
4.1.1.2. Increasing Demand for Protein Biologics
4.1.2. Restraints
4.1.2.1. High Product Costs
4.1.3. Opportunity
4.1.3.1. The Growing Interest in The Heterologous Production of Proteins
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Global Recession Analysis
9. Artificial Intelligence Impact Analysis
10. By Proteins
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Proteins
10.1.2. Market Attractiveness Index, By Proteins
10.2. Membrane Proteins
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Proteases
10.4. Kinases
10.5. Others
11. By Technology
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.1.2. Market Attractiveness Index, By Technology
11.2. Cell-free Protein Synthesis*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Prokaryotic Expression Systems
11.4. Gene Fusion Systems
11.5. SUMO Fusion System
11.6. Others
12. By Application
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.1.2. Market Attractiveness Index, By Application
12.2. Drug Discovery*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Protein Purification
12.4. Protein Therapeutics
12.5. Disease Diagnostics and Monitoring
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Proteins
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.6.1. The U.S.
13.2.6.2. Canada
13.2.6.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Proteins
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.6.1. Germany
13.3.6.2. The U.K.
13.3.6.3. France
13.3.6.4. Italy
13.3.6.5. Spain
13.3.6.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Proteins
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.6.1. Brazil
13.4.6.2. Argentina
13.4.6.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Proteins
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.6.1. China
13.5.6.2. India
13.5.6.3. Japan
13.5.6.4. Australia
13.5.6.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Proteins
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Market Share Analysis
14.3. Mergers and Acquisitions Analysis
15. Company Profiles
15.1. Merck KGaA*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Thermo Fisher Scientific
15.3. Bio-Rad Laboratories, Inc.
15.4. R&D Systems (Bio-Techne)
15.5. Lucigen (LGC Group)
15.6. LifeSensors Inc.
15.7. BioLegend, Inc. (PerkinElmer Inc.)
15.8. Reaction Biology (Cobepa)
15.9. OriGene Technologies, Inc.
15.10. Enzo Life Sciences, Inc.
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us

언급된 주요 기업들

Merck KGaA, 4.	Key Developments, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., R&D Systems (Bio-Techne), Lucigen (LGC Group), LifeSensors Inc., BioLegend, Inc. (PerkinElmer Inc.), Reaction Biology (Cobepa), OriGene Technologies, Inc., Enzo Life Sciences, Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Difficult-to-Express Proteins Market Value, By Proteins, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Difficult-to-Express Proteins Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Difficult-to-Express Proteins Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Difficult-to-Express Proteins Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Difficult-to-Express Proteins Market Value, By Proteins, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Difficult-to-Express Proteins Market Value, By Proteins, 2022-2031 (US$ Million)

Table 7 Global Difficult-to-Express Proteins Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Difficult-to-Express Proteins Market Value, By Technology, 2022-2031 (US$ Million)

Table 9 Global Difficult-to-Express Proteins Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Difficult-to-Express Proteins Market Value, By Application, 2022-2031 (US$ Million)

Table 11 Global Difficult-to-Express Proteins Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Difficult-to-Express Proteins Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Difficult-to-Express Proteins Market Value, By Proteins, 2022-2031 (US$ Million)

Table 14 North America Difficult-to-Express Proteins Market Value, By Technology, 2022-2031 (US$ Million)

Table 15 North America Difficult-to-Express Proteins Market Value, By Application, 2022-2031 (US$ Million)

Table 16 North America Difficult-to-Express Proteins Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Difficult-to-Express Proteins Market Value, By Proteins, 2022-2031 (US$ Million)

Table 18 South America Difficult-to-Express Proteins Market Value, By Technology, 2022-2031 (US$ Million)

Table 19 South America Difficult-to-Express Proteins Market Value, By Application, 2022-2031 (US$ Million)

Table 20 South America Difficult-to-Express Proteins Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Difficult-to-Express Proteins Market Value, By Proteins, 2022-2031 (US$ Million)

Table 22 Europe Difficult-to-Express Proteins Market Value, By Technology, 2022-2031 (US$ Million)

Table 23 Europe Difficult-to-Express Proteins Market Value, By Application, 2022-2031 (US$ Million)

Table 24 Europe Difficult-to-Express Proteins Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Difficult-to-Express Proteins Market Value, By Proteins, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Difficult-to-Express Proteins Market Value, By Technology, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Difficult-to-Express Proteins Market Value, By Application, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Difficult-to-Express Proteins Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Difficult-to-Express Proteins Market Value, By Proteins, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Difficult-to-Express Proteins Market Value, By Technology, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Difficult-to-Express Proteins Market Value, By Application, 2022-2031 (US$ Million)

Table 32 Merck KGaA: Overview

Table 33 Merck KGaA: Product Portfolio

Table 34 Merck KGaA: Key Developments

Table 35 Thermo Fisher Scientific: Overview

Table 36 Thermo Fisher Scientific: Product Portfolio

Table 37 Thermo Fisher Scientific: Key Developments

Table 38 Bio-Rad Laboratories, Inc.: Overview

Table 39 Bio-Rad Laboratories, Inc.: Product Portfolio

Table 40 Bio-Rad Laboratories, Inc.: Key Developments

Table 41 R&D Systems (Bio-Techne): Overview

Table 42 R&D Systems (Bio-Techne): Product Portfolio

Table 43 R&D Systems (Bio-Techne): Key Developments

Table 44 Lucigen (LGC Group): Overview

Table 45 Lucigen (LGC Group): Product Portfolio

Table 46 Lucigen (LGC Group): Key Developments

Table 47 LifeSensors Inc.: Overview

Table 48 LifeSensors Inc.: Product Portfolio

Table 49 LifeSensors Inc.: Key Developments

Table 50 BioLegend, Inc. (PerkinElmer Inc.): Overview

Table 51 BioLegend, Inc. (PerkinElmer Inc.): Product Portfolio

Table 52 BioLegend, Inc. (PerkinElmer Inc.): Key Developments

Table 53 Reaction Biology (Cobepa): Overview

Table 54 Reaction Biology (Cobepa): Product Portfolio

Table 55 Reaction Biology (Cobepa): Key Developments

Table 56 OriGene Technologies, Inc.: Overview

Table 57 OriGene Technologies, Inc.: Product Portfolio

Table 58 OriGene Technologies, Inc.: Key Developments

Table 59 Enzo Life Sciences, Inc.: Overview

Table 60 Enzo Life Sciences, Inc.: Product Portfolio

Table 61 Enzo Life Sciences, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 2 Global Difficult-to-Express Proteins Market Share, By Proteins, 2022 & 2031 (%)

Figure 3 Global Difficult-to-Express Proteins Market Share, By Technology, 2022 & 2031 (%)

Figure 4 Global Difficult-to-Express Proteins Market Share, By Application, 2022 & 2031 (%)

Figure 5 Global Difficult-to-Express Proteins Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Difficult-to-Express Proteins Market Y-o-Y Growth, By Proteins, 2022-2031 (%)

Figure 7 Membrane Proteins Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 8 Proteases Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 9 Kinases Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 10 Others Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 11 Global Difficult-to-Express Proteins Market Y-o-Y Growth, By Technology, 2022-2031 (%)

Figure 12 Cell-free Protein Synthesis Technology in Global Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 13 Prokaryotic Expression Systems Technology in Global Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 14 Gene Fusion Systems Technology in Global Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 15 SUMO Fusion System Technology in Global Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 16 Others Technology in Global Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 17 Global Difficult-to-Express Proteins Market Y-o-Y Growth, By Application, 2022-2031 (%)

Figure 18 Drug Discovery Application in Global Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 19 Protein Purification Application in Global Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 20 Protein Therapeutics Application in Global Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 21 Disease Diagnostics and Monitoring Application in Global Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 22 Global Difficult-to-Express Proteins Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 23 North America Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 24 Asia-Pacific Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 25 Europe Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 26 South America Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 27 Middle East and Africa Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 28 North America Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 29 North America Difficult-to-Express Proteins Market Share, By Proteins, 2022 & 2031 (%)

Figure 30 North America Difficult-to-Express Proteins Market Share, By Technology, 2022 & 2031 (%)

Figure 31 North America Difficult-to-Express Proteins Market Share, By Application, 2022 & 2031 (%)

Figure 32 North America Difficult-to-Express Proteins Market Share, By Country, 2022 & 2031 (%)

Figure 33 South America Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 34 South America Difficult-to-Express Proteins Market Share, By Proteins, 2022 & 2031 (%)

Figure 35 South America Difficult-to-Express Proteins Market Share, By Technology, 2022 & 2031 (%)

Figure 36 South America Difficult-to-Express Proteins Market Share, By Application, 2022 & 2031 (%)

Figure 37 South America Difficult-to-Express Proteins Market Share, By Country, 2022 & 2031 (%)

Figure 38 Europe Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 39 Europe Difficult-to-Express Proteins Market Share, By Proteins, 2022 & 2031 (%)

Figure 40 Europe Difficult-to-Express Proteins Market Share, By Technology, 2022 & 2031 (%)

Figure 41 Europe Difficult-to-Express Proteins Market Share, By Application, 2022 & 2031 (%)

Figure 42 Europe Difficult-to-Express Proteins Market Share, By Country, 2022 & 2031 (%)

Figure 43 Asia-Pacific Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 44 Asia-Pacific Difficult-to-Express Proteins Market Share, By Proteins, 2022 & 2031 (%)

Figure 45 Asia-Pacific Difficult-to-Express Proteins Market Share, By Technology, 2022 & 2031 (%)

Figure 46 Asia-Pacific Difficult-to-Express Proteins Market Share, By Application, 2022 & 2031 (%)

Figure 47 Asia-Pacific Difficult-to-Express Proteins Market Share, By Country, 2022 & 2031 (%)

Figure 48 Middle East & Africa Difficult-to-Express Proteins Market Value, 2022-2031 (US$ Million)

Figure 49 Middle East & Africa Difficult-to-Express Proteins Market Share, By Proteins, 2022 & 2031 (%)

Figure 50 Middle East & Africa Difficult-to-Express Proteins Market Share, By Technology, 2022 & 2031 (%)

Figure 51 Middle East & Africa Difficult-to-Express Proteins Market Share, By Application, 2022 & 2031 (%)

Figure 52 Merck KGaA: Financials

Figure 53 Thermo Fisher Scientific: Financials

Figure 54 Bio-Rad Laboratories, Inc.: Financials

Figure 55 R&D Systems (Bio-Techne): Financials

Figure 56 Lucigen (LGC Group): Financials

Figure 57 LifeSensors Inc.: Financials

Figure 58 BioLegend, Inc. (PerkinElmer Inc.): Financials

Figure 59 Reaction Biology (Cobepa): Financials

Figure 60 OriGene Technologies, Inc.: Financials

Figure 61 Enzo Life Sciences, Inc.: Financials

글로벌 난표현 단백질 시장 – 2023-2030

Global Difficult-to-Express Proteins Market - 2023-2030